Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Malik Mumtaz Taqi, Muhammad Faisal & Hadar Zaman. (2019) OPRM1 A118G Polymorphisms and Its Role in Opioid Addiction: Implication on Severity and Treatment Approaches. Pharmacogenomics and Personalized Medicine 12, pages 361-368.
Read now
Read now
Articles from other publishers (32)
Frank Breve, Lisa Batastini, Jo Ann K LeQuang & Gina Marchando. (2022) Mobile Narcotic Treatment Programs: On the Road Again?. Cureus.
Crossref
Crossref
Albert Lin & Anuj Aggarwal. 2022. Treatments, Mechanisms, and Adverse Reactions of Anesthetics and Analgesics. Treatments, Mechanisms, and Adverse Reactions of Anesthetics and Analgesics
55
61
.
Ilunga Kamika, Shohreh Azizi, Adolph A. Muleja, Ramganesh Selvarajan, Mohamed Azab El-Liethy, Bheki B. Mamba & Thabo T.I. Nkambule. (2021) The occurrence of opioid compounds in wastewater treatment plants and their receiving water bodies in Gauteng province, South Africa. Environmental Pollution 290, pages 118048.
Crossref
Crossref
Allison Marmel & Nikki Bozinoff. (2020) Punitive discontinuation of opioid agonist therapy during incarceration. International Journal of Prisoner Health 16:4, pages 337-342.
Crossref
Crossref
Kaytlyn M. Crowe, Zain Siddiqui, Victoria Harbour, KaKyung Kim, Shareef Syed, Reshma Paul, Abhishek Roy, Ruhi Naik, Kayla Mitchell, Aryan Mahajan, Biplab Sarkar & Vivek A. Kumar. (2020) Evaluation of Injectable Naloxone-Releasing Hydrogels. ACS Applied Bio Materials 3:11, pages 7858-7864.
Crossref
Crossref
Brian Maila, Anatolii Tsarkov, Petro Petlovanyi, Gaise Kweku & Evans Musonda. (2020) Treatment of Opioid Use Disorder With Buprenorphine-Naloxone at Chainama Hills College Hospital in Lusaka, Zambia: A Case Report. European Journal of Medical and Health Sciences 2:4.
Crossref
Crossref
Medine Giynas Ayhan, Hilal Seven, Ali Hakan Ozturk, Seda Kirci Ercan, Basak Demirel & İbrahim Eren. (2018) Alexithymia and Self-Esteem in a Sample of Opioid Dependent Males: a Controlled Study. International Journal of Mental Health and Addiction 18:4, pages 968-979.
Crossref
Crossref
Marte Handal, Svetlana Skurtveit, Milada Mahic, Inger Øhman, Birgitta Norstedt Wikner, Christian Tjagvad, Helle Kieler, Erja Halmesmäki & Ingunn Olea Lund. (2020) Opioid maintenance treatment of pregnant women in the Scandinavian countries. Nordic Studies on Alcohol and Drugs 37:3, pages 298-312.
Crossref
Crossref
Tara Carney, Marie Claire Van Hout, Ian Norman, Siphokazi Dada, Nandi Siegfried & Charles DH Parry. (2020) Dihydrocodeine for detoxification and maintenance treatment in individuals with opiate use disorders. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Dharushana Muthulingam, Joshua Bia, Lynn M. Madden, Scott O. Farnum, Declan T. Barry & Frederick L. Altice. (2019) Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support. Journal of Substance Abuse Treatment 100, pages 18-28.
Crossref
Crossref
Nikita N. Burke, Mehnaz Ferdousi, Daniel R. Deaver, David P. Finn, Michelle Roche & John P. Kelly. (2019) Locomotor and anti-immobility effects of buprenorphine in combination with the opioid receptor modulator samidorphan in rats. Neuropharmacology 146, pages 327-336.
Crossref
Crossref
Jamshid Ahmadi, Mina Sefidfard Jahromi & Zahra Ehsaei. (2018) The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial. Trials 19:1.
Crossref
Crossref
Young-A Heo & Lesley J. Scott. (2018) Buprenorphine/Naloxone (Zubsolv®): A Review in Opioid Dependence. CNS Drugs 32:9, pages 875-882.
Crossref
Crossref
Gabrielle S. Donahue, Noortje Catherine Hagemeijer & Anne Holly Johnson. (2018) How Will the Foot and Ankle Orthopedic Community Respond to the Growing Opioid Epidemic?. Foot & Ankle Orthopaedics 3:3, pages 247301141876446.
Crossref
Crossref
Richard C. Crist, Toni-Kim Clarke & Wade H. Berrettini. (2018) Pharmacogenetics of Opioid Use Disorder Treatment. CNS Drugs 32:4, pages 305-320.
Crossref
Crossref
Jamshid Ahmadi & Mina Sefidfard Jahromi. (2018) Fast Effect of Buprenorphine on Opioid-dependent Patients with Suicidal Ideation: A Novel Approach. International Journal of High Risk Behaviors and Addiction 7:2.
Crossref
Crossref
Mersha Chetty, James J. Kenworthy, Sue Langham, Andrew Walker & William C. N. Dunlop. (2017) A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence. Addiction Science & Clinical Practice 12:1.
Crossref
Crossref
Eric Urnoski. (2017) Why is buprenorphine coformulated with naloxone?. Journal of the American Academy of Physician Assistants 30:11, pages 44-45.
Crossref
Crossref
J. Rick Turner. (2017) Commissioner Gottlieb and the Crusade Against Opioid Abuse: Baptism by Fire. Therapeutic Innovation & Regulatory Science 51:4, pages 400-403.
Crossref
Crossref
O. J. Michael Coppes & Christine N. Sang. (2017) Indications for Opioid Antagonists. Current Pain and Headache Reports 21:6.
Crossref
Crossref
Corey Hassell, Kirsten Wilkins & Louis A. Trevisan. (2017) Pharmacology of Geriatric Substance Use Disorders: Considerations and Future Directions. Current Treatment Options in Psychiatry 4:1, pages 102-115.
Crossref
Crossref
Nalini Vadivelu, Alice M. Kai, Vijay Kodumudi, Richard Zhu & Roberta Hines. (2017) Pain Management of Patients with Substance Abuse in the Ambulatory Setting. Current Pain and Headache Reports 21:2.
Crossref
Crossref
Michael Soyka, Jens Strehle, Jürgen Rehm, Gerhard Bühringer & Hans-Ulrich Wittchen. (2017) Six-Year Outcome of Opioid Maintenance Treatment in Heroin-Dependent Patients: Results from a Naturalistic Study in a Nationally Representative Sample. European Addiction Research 23:2, pages 97-105.
Crossref
Crossref
Amanda A. Westlake & Mark P. Eisenberg. (2017) Infectious Disease (ID) Learning Unit: What the ID Clinician Needs to Know About Buprenorphine Treatment for Opioid Use Disorder. Open Forum Infectious Diseases 4:1.
Crossref
Crossref
Brian Reed & Mary Jeanne Kreek. 2017. Hormones, Brain and Behavior. Hormones, Brain and Behavior
403
420
.
J. Rick Turner, Dilip R. Karnad & Snehal KothariJ. Rick Turner, Dilip R. Karnad & Snehal Kothari. 2017. Cardiovascular Safety in Drug Development and Therapeutic Use. Cardiovascular Safety in Drug Development and Therapeutic Use
305
330
.
Shefali Srivastava, Emily A. Fergason-Cantrell, Roger I. Nahas & John R. Lever. (2016) Synthesis and opioid receptor binding of indium (III) and [111In]-labeled macrocyclic conjugates of diprenorphine: novel ligands designed for imaging studies of peripheral opioid receptors. Tetrahedron 72:40, pages 6127-6135.
Crossref
Crossref
Michael Soyka & Jochen Mutschler. (2016) Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine. Progress in Neuro-Psychopharmacology and Biological Psychiatry 70, pages 148-161.
Crossref
Crossref
Marie Claire Van Hout, Ide Delargy, Gerry Ryan, Siobhan Flanagan & Hugh Gallagher. (2015) Dependence on Over the Counter (OTC) Codeine Containing Analgesics: Treatment and Recovery with Buprenorphine Naloxone. International Journal of Mental Health and Addiction 14:5, pages 873-883.
Crossref
Crossref
Marc A. Schuckit. (2016) Treatment of Opioid-Use Disorders. New England Journal of Medicine 375:4, pages 357-368.
Crossref
Crossref
Tara Carney, Marie Claire Van Hout, Ian Norman, Siphokazi Dada & Charles DH Parry. (2016) Dihydrocodeine for detoxification and maintenance treatment in illicit opiate-dependent individuals. Cochrane Database of Systematic Reviews.
Crossref
Crossref
H. Dolengevich Segal, B. Rodríguez Salgado, F. Mora Mínguez & J. Quintero. (2015) Trastornos por consumo de sustancias y fármacos. Medicine - Programa de Formación Médica Continuada Acreditado 11:86, pages 5137-5143.
Crossref
Crossref